These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2070363

  • 1. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
    Olanow CW, Nakano K, Nausieda P, Tetrud JA, Manyam B, Last B, Block G, Liss C, Bush D.
    Clin Neuropharmacol; 1991 Jun; 14(3):235-40. PubMed ID: 2070363
    [Abstract] [Full Text] [Related]

  • 2. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 3. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA.
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [Abstract] [Full Text] [Related]

  • 4. Trial of Sinemet CR4 in patients with Parkinson's disease.
    Anderson TJ, Ewer TC, Gilchrist NL, Donaldson IM.
    N Z Med J; 1992 Mar 11; 105(929):81-2. PubMed ID: 1545941
    [Abstract] [Full Text] [Related]

  • 5. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT, Morris JL, Román GC, Imke SC, Elias JW.
    Arch Neurol; 1988 Aug 11; 45(8):861-4. PubMed ID: 3395259
    [Abstract] [Full Text] [Related]

  • 6. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
    Bush DF, Liss CL, Morton A.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
    [Abstract] [Full Text] [Related]

  • 7. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G, Liss C, Reines S, Irr J, Nibbelink D.
    Eur Neurol; 1997 Nov 11; 37(1):23-7. PubMed ID: 9018028
    [Abstract] [Full Text] [Related]

  • 8. Sinemet CR in Parkinson's disease.
    Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R.
    Nebr Med J; 1991 Jan 11; 76(1):8-10. PubMed ID: 1997878
    [Abstract] [Full Text] [Related]

  • 9. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 10. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 11. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS.
    Neurology; 1987 May 11; 37(5):875-8. PubMed ID: 3574696
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
    Wolters EC, Horstink MW, Roos RA, Jansen EN.
    Clin Neurol Neurosurg; 1992 May 11; 94(3):205-11. PubMed ID: 1327609
    [Abstract] [Full Text] [Related]

  • 13. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 14. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
    Grandas F, Martínez-Martín P, Linazasoro G.
    J Neurol; 1998 May 11; 245 Suppl 1():S31-3. PubMed ID: 9617721
    [Abstract] [Full Text] [Related]

  • 15. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 16. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM, Breck L, Kutt H, McDowell FH.
    Neurology; 1987 Feb 11; 37(2):233-41. PubMed ID: 3808304
    [Abstract] [Full Text] [Related]

  • 17. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
    Wolters EC, Tesselaar HJ.
    J Neurol; 1996 Mar 11; 243(3):235-40. PubMed ID: 8936353
    [Abstract] [Full Text] [Related]

  • 18. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
    Rodnitzky RL, Dickins QS, Dobson J.
    Neurology; 1989 Nov 11; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
    [Abstract] [Full Text] [Related]

  • 19. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
    Bowes SG, Dobbs RJ, Henley M, Charlett A, O'Neill CJ, Nicholson PW, Purkiss AG, Weller C, Dobbs SM.
    Eur J Clin Pharmacol; 1992 Nov 11; 43(5):483-9. PubMed ID: 1483485
    [Abstract] [Full Text] [Related]

  • 20. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Nov 11; 19(2):101-6. PubMed ID: 2665626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.